pargyline has been researched along with Androgen-Independent Prostatic Cancer in 1 studies
Pargyline: A monoamine oxidase inhibitor with antihypertensive properties.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pargyline was given intraperitoneally or not after castration (implemented with Bilateral orchidectomy), then PSA levels in serum and tumor were determined to assess time to androgen-independent progression." | 1.42 | Inhibition of LSD1 by Pargyline inhibited process of EMT and delayed progression of prostate cancer in vivo. ( Guo, J; He, L; Jiang, G; Liu, X; Wang, M; Wang, Z; Weng, X, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, M | 1 |
| Liu, X | 1 |
| Guo, J | 1 |
| Weng, X | 1 |
| Jiang, G | 1 |
| Wang, Z | 1 |
| He, L | 1 |
1 other study available for pargyline and Androgen-Independent Prostatic Cancer
| Article | Year |
|---|---|
Inhibition of LSD1 by Pargyline inhibited process of EMT and delayed progression of prostate cancer in vivo.
Topics: Animals; Antihypertensive Agents; Antineoplastic Agents; Cadherins; Cell Line, Tumor; Cell Movement; | 2015 |